MedTrace Logo

Efficacy of a Standardized Centella Asiatica Extract in Patients With Temporomandibular Disorder

NCT06231212 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2024-02-07

No results posted yet for this study

Summary

The goal of this clinical trial is to test analgesic effect of ECa 233 in subjects with TMD. The main questions it aims to answer are:

* Can ECa 233 reduce pain intensity score in subjects with acute TMD?
* Can ECa 233 increase jaw functional movements in subjects with acute TMD? Participants will be separated into four groups, including placebo, ibuprofen, low-dosed Eca and high-dosed Eca groups.

Conditions

  • Temporomandibular Disorder

Interventions

DRUG

ECa 233

Intervention groups are separated into group A and group B. Group A takes capsules containing 250 mg of ECa 233 and group B takes capsules containing 500 mg of ECa 233.

DRUG

Ibuprofen

Ibuprofen group was given capsules containing 200 mg of ibuprofen

OTHER

Placebo

Placebo-controlled group received capsules containing 250 mg of lactose

Sponsors & Collaborators

  • Chulalongkorn University

    lead OTHER

Principal Investigators

  • Prangtip Potewiratnanond · Chulalongkorn University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-05
Primary Completion
2021-09-01
Completion
2022-12-30

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06231212 on ClinicalTrials.gov